Impact of hemodialysis on clinical and angiographic outcomes in in-stent restenotic lesions following optical coherence tomography-guided drug-coated balloon treatment.
Drug-coated balloon
Hemodialysis
Restenosis
Stent
Journal
Cardiovascular intervention and therapeutics
ISSN: 1868-4297
Titre abrégé: Cardiovasc Interv Ther
Pays: Japan
ID NLM: 101522043
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
24
07
2020
accepted:
01
10
2020
pubmed:
14
10
2020
medline:
26
11
2021
entrez:
13
10
2020
Statut:
ppublish
Résumé
Hemodialysis (HD) is associated with a high in-stent restenosis (ISR) rate even in the second-generation era. Drug-coated balloons (DCB) generally provide excellent clinical outcomes in patients with ISR lesions. Nonetheless, safety and efficacy of DCB for ISR lesions in HD patients are largely unknown. A total of 17 centers across Japan participated in this study. Patients were eligible for the study if ISR lesions were treated with DCB. Enrolled patients were divided into 2 groups (HD and non-HD groups). Angiographic, OCT, and clinical outcomes were compared between the HD and the non-HD groups. A total of 210 patients were enrolled (36 patients in the HD group, and 174 patients in the non-HD group). At 8 months, the binary restenosis rate was significantly higher (26.3% versus 11.3%, p = 0.02) and in-segment late loss was significantly higher (0.49 ± 0.61 mm versus 0.23 ± 0.33 mm, p = 0.02) in the HD group than the non-HD group. In the OCT analyses, change of minimum stent area between post- and pre-procedure was significantly smaller in the HD group compared to the non-HD group (0.08 ± 0.95 mm
Identifiants
pubmed: 33048289
doi: 10.1007/s12928-020-00718-7
pii: 10.1007/s12928-020-00718-7
doi:
Substances chimiques
Coated Materials, Biocompatible
0
Banques de données
ClinicalTrials.gov
['NCT02300454']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
429-435Informations de copyright
© 2020. Japanese Association of Cardiovascular Intervention and Therapeutics.
Références
Aoki J, Ikari Y. Cardiovascular disease in patients with end-stage renal disease on hemodialysis. Ann Vasc Dis. 2017;10:327–37.
doi: 10.3400/avd.ra.17-00051
Tsai TT, Messenger JC, Brennan JM, Patel UD, Dai D, Piana RN, et al. Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database. J Am Coll Cardiol. 2011;58:1859–69.
doi: 10.1016/j.jacc.2011.06.056
Lee JM, Kang J, Lee E, Hwang D, Rhee TM, Park J, et al. Chronic Kidney disease in the second-generation drug-eluting stent era: pooled analysis of the korean multicenter drug-eluting stent registry. JACC Cardiovasc Interv. 2016;9:2097–109.
doi: 10.1016/j.jcin.2016.06.051
Aoki J, Kozuma K, Awata M, Nanasato M, Shiode N, Tanabe K, et al. Five-year clinical outcomes of everolimus-eluting stents from the post marketing study of CoCr-EES (XIENCE V/PROMUS) in Japan. Cardiovasc Interv Ther. 2019;34:40–6.
doi: 10.1007/s12928-018-0515-z
Habara S, Kadota K, Shimada T, Ohya M, Amano H, Izawa Y, et al. Late restenosis after paclitaxel-coated balloon angioplasty occurs in patients with drug-eluting stent restenosis. J Am Coll Cardiol. 2015;66:14–22.
doi: 10.1016/j.jacc.2015.05.002
Alfonso F, Perez-Vizcayno MJ, Garcia Del Blanco B, Otaegui I, Masotti M, Zueco J, et al. Long-term results of everolimus-eluting stents versus drug-eluting balloons in patients with bare-metal in-stent restenosis: 3-year follow-up of the RIBS V clinical trial. JACC Cardiovasc Interv. 2016;9:1246–55.
doi: 10.1016/j.jcin.2016.03.037
Miura K, Kadota K, Habara S, Shimada T, Ohya M, Amano H, et al. Five-year outcomes after paclitaxel-coated balloon angioplasty for drug-eluting stent restenosis. Am J Cardiol. 2017;119:365–71.
doi: 10.1016/j.amjcard.2016.10.030
Alfonso F, Perez-Vizcayno MJ, Cuesta J, Garcia Del Blanco B, Garcia-Touchard A, Lopez-Minguez JR, et al. 3-Year clinical follow-up of the RIBS IV clinical trial: a prospective randomized study of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis in coronary arteries previously treated with drug-eluting stents. JACC Cardiovasc Interv. 2018;11:981–91.
doi: 10.1016/j.jcin.2018.02.037
Aoki J, Nakazawa G, Ando K, Nakamura S, Tobaru T, Sakurada M, et al. Effect of combination of non-slip element balloon and drug-coating balloon for in-stent restenosis lesions (ELEGANT study). J Cardiol. 2019;74:436–42.
doi: 10.1016/j.jjcc.2019.04.011
Taguchi I, Kageyama M, Kanaya T, Abe S, Node K, Inoue T. Clinical significance of non-slip element balloon angioplasty for patients of coronary artery disease: a preliminary report. J Cardiol. 2014;63:19–23.
doi: 10.1016/j.jjcc.2013.06.009
Yabushita H, Kawamoto H, Fujino Y, Tahara S, Horikoshi T, Tada M, et al. Clinical outcomes of drug-eluting balloon for in-stent restenosis based on the number of metallic layers. Circ Cardiovasc Interv. 2018;11:e005935.
doi: 10.1161/CIRCINTERVENTIONS.117.005935
Koiwaya H, Watanabe N, Kuriyama N, Nishino S, Ogata K, Kimura T, et al. Predictors of recurrent in-stent restenosis after paclitaxel-coated balloon angioplasty. Circ J. 2017;81:1286–92.
doi: 10.1253/circj.CJ-17-0095
Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol. 2003;14:1927–39.
doi: 10.1097/01.ASN.0000069165.79509.42
Nakamura S, Ishibashi-Ueda H, Niizuma S, Yoshihara F, Horio T, Kawano Y. Coronary calcification in patients with chronic kidney disease and coronary artery disease. Clin J Am Soc Nephrol. 2009;4:1892–900.
doi: 10.2215/CJN.04320709
Kiriyama H, Kodera S, Minatsuki S, Kaneko H, Kikuchi H, Kiyosue A, et al. Short-term and long-term efficacy of drug-coated balloon for in-stent restenosis in hemodialysis patients with coronary artery disease. Int Heart J. 2019;60:1070–6.
doi: 10.1536/ihj.18-533
Kubo T, Shinke T, Okamura T, Hibi K, Nakazawa G, Morino Y, et al. Optical frequency domain imaging vs. intravascular ultrasound in percutaneous coronary intervention (OPINION trial): one-year angiographic and clinical results. Eur Heart J. 2017;38:3139–47.
doi: 10.1093/eurheartj/ehx351
Otake H, Kubo T, Takahashi H, Shinke T, Okamura T, Hibi K, at al. Optical frequency domain imaging versus intravascular ultrasound in percutaneous coronary intervention (OPINION Trial): results from the OPINION imaging study. JACC Cardiovasc Imaging. 2018;11:111–23.
doi: 10.1016/j.jcmg.2017.06.021
Bangalore S, Maron DJ, O'Brien SM, Fleg JL, Kretov EI, Briguori C, et al. Management of coronary disease in patients with advanced kidney disease. N Engl J Med. 2020;382:1608–18.
doi: 10.1056/NEJMoa1915925